AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8.
ByAinvest
Tuesday, Aug 12, 2025 7:15 am ET1min read
Iterum Therapeutics plc (ITRM) announced that Director Michael W. Dunne acquired 15,000 shares at a price of $0.72 per share on August 8, 2025.
Dublin, Ireland — July 02, 2025 — Director Michael W. Dunne of Iterum Therapeutics plc (ITRM) has acquired 15,000 shares of the company at a price of $0.72 per share on August 8, 2025, according to a recent SEC Form 4 filing [1]. This transaction was made pursuant to a contract, instruction, or written plan for the purchase of equity securities, which satisfies the affirmative defense conditions of Rule 10b5-1(c) [1].The acquisition follows a period of financial challenges for the company, as it reported a net loss of $6.51 million for the second quarter and $11.4 million for the six months ended June 30, 2025. The company's basic and diluted loss per share from continuing operations for the second quarter was $0.16, compared to $0.3 a year ago. For the six months, the basic and diluted loss per share was $0.31, compared to $0.76 a year ago [2].
Despite these losses, the company has been making progress in its pipeline. Iterum Therapeutics is expected to launch its oral antibiotic ORLYNVAH™ for uncomplicated urinary tract infections (uUTIs) in August 2025. The company has also entered into a partnership with EVERSANA Life Science Services, LLC for the commercialization of ORLYNVAH™ in the U.S. [3].
The acquisition of shares by Dunne, a 10% owner and director of the company, may indicate confidence in the company's future prospects, particularly given the upcoming launch of ORLYNVAH™. However, investors should also consider the company's recent financial performance and the competitive landscape in the antibiotic market.
References:
[1] https://www.sec.gov/Archives/edgar/data/1659323/000095017025106908/xslF345X05/ownership.xml
[2] https://www.marketscreener.com/news/iterum-therapeutics-plc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-june-30-ce7c5ed8dc8ff626
[3] https://www.globenewswire.com/news-release/2025/08/05/3127171/0/en/Iterum-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet